{"id":47822,"date":"2022-08-30T23:01:43","date_gmt":"2022-08-30T21:01:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/"},"modified":"2022-08-30T23:01:43","modified_gmt":"2022-08-30T21:01:43","slug":"spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/","title":{"rendered":"Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference"},"content":{"rendered":"
\n

SAN FRANCISCO–(BUSINESS WIRE)–$SPRB<\/a> #Tildacerfont<\/a>—Spruce Biosciences, Inc<\/a>. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Samir Gharib, President and Chief Financial Officer, will present at the H.C. Wainwright 24th<\/sup> Annual Global Investment Conference on September 12, 2022 at 5:00 pm ET.\n<\/p>\n

<\/a><\/p>\n

\nInterested parties can access the live webcast here<\/a>. An archived copy of the webcast will be available on the events section<\/a> of the company\u2019s investor relations website<\/a> for approximately 30 days.\n<\/p>\n

\nAbout Spruce Biosciences<\/b>\n<\/p>\n

\nSpruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com<\/a> and follow us on Twitter @Spruce_Bio<\/a>, LinkedIn<\/a>, Facebook<\/a> and YouTube<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact<\/b>
Will Zasadny
\n
Canale Communications
\n
(619) 961-8848
\n
will.zasadny@evokegroup.com<\/a>
media@sprucebiosciences.com<\/a>\n<\/p>\n

\nInvestors<\/b>
Xuan Yang
\n
Solebury Trout
\n
(415) 971-9412
\n
xyang@soleburytrout.com<\/a>
investors@sprucebiosciences.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO–(BUSINESS WIRE)–$SPRB #Tildacerfont—Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Samir Gharib, President and Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022 at 5:00 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47822","6":"format-standard","7":"category-industry"},"yoast_head":"\nSpruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO–(BUSINESS WIRE)–$SPRB #Tildacerfont—Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Samir Gharib, President and Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022 at 5:00 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-30T21:01:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220830005053\/en\/789688\/21\/Picture1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference\",\"datePublished\":\"2022-08-30T21:01:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\\\/\"},\"wordCount\":233,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220830005053\\\/en\\\/789688\\\/21\\\/Picture1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\\\/\",\"name\":\"Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220830005053\\\/en\\\/789688\\\/21\\\/Picture1.jpg\",\"datePublished\":\"2022-08-30T21:01:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220830005053\\\/en\\\/789688\\\/21\\\/Picture1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220830005053\\\/en\\\/789688\\\/21\\\/Picture1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend","og_description":"SAN FRANCISCO–(BUSINESS WIRE)–$SPRB #Tildacerfont—Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Samir Gharib, President and Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022 at 5:00 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-30T21:01:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220830005053\/en\/789688\/21\/Picture1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference","datePublished":"2022-08-30T21:01:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/"},"wordCount":233,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220830005053\/en\/789688\/21\/Picture1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/","url":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/","name":"Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220830005053\/en\/789688\/21\/Picture1.jpg","datePublished":"2022-08-30T21:01:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220830005053\/en\/789688\/21\/Picture1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220830005053\/en\/789688\/21\/Picture1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/spruce-biosciences-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47822"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47822\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47822"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47822"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}